HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19
Intro: The concept of training immunity originally developed for other diseases has gained attraction during the epidemic. Several clinical trials and epidemiological analyses of populations previously immunized with BCG and other vaccines were the focus of scientific discussions. Here we show the a...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223001583 |
| _version_ | 1797824627063390208 |
|---|---|
| author | G. Guillen M. Limonta V. Muzio Z. Cinza G. Lemos G. Chinea A. Martin D. Gonzalez-Roche I. Valdes Y. Mendosa J. Aguiar M. Bequet G. Marques J. Zamora E. Penton E. Iglesias J. Aguilar O. Cruz M. Ayala E. Pimentel E. Martinez |
| author_facet | G. Guillen M. Limonta V. Muzio Z. Cinza G. Lemos G. Chinea A. Martin D. Gonzalez-Roche I. Valdes Y. Mendosa J. Aguiar M. Bequet G. Marques J. Zamora E. Penton E. Iglesias J. Aguilar O. Cruz M. Ayala E. Pimentel E. Martinez |
| author_sort | G. Guillen |
| collection | DOAJ |
| description | Intro: The concept of training immunity originally developed for other diseases has gained attraction during the epidemic. Several clinical trials and epidemiological analyses of populations previously immunized with BCG and other vaccines were the focus of scientific discussions. Here we show the activation of innate immunity markers both at mucosal and systemic levels with a mucosal vaccine CIGB2020 (HeberNasvacTM) containing virus-like particles (HBsAg) and nucleocapsid particle (HBcAg) of the hepatitis B virus. Moreover, the immune potentiating capacity of the HBcAg combined with RBD protein was used to formulate a specific mucosal vaccine candidate against SARS-CoV-2 (MambisaTM). Methods: With CIGB 2020 (100µg HBsAg and 100 µg HBcAg) were conducted two proof of concept trials in human volunteers and a Phase I-II open, randomized, and controlled trial in 46 volunteers older than 60 years, symptomatic or close contact of COVID-19 patients. The volunteers were randomly assigned to the treatment group or not treated group. The nasal spray was administered to the treatment group on days 0, 7, and 14 together with daily sublingual administrations. Mucosal and serum samples were collected on days 0, 4, and 8. With MambisaTM vaccine (50µg RBD and 40 µg HBcAg) was conducted one proof of concept trial and a Phase I-II open and randomized trial in 1131 volunteers 19 to 60 years old, evaluating three different devices for nasal administration. All the volunteers gave written informed consent. Findings: CIGB2020 activates interferon-induced genes and TLR 3, 7, and 8 at the level of oropharyngeal mucosa and PBMC. Monocyte and lymphocyte populations were also activated. One dose of the MambisaTM vaccine induces high levels of specific IgG. The serum and mucosal antibodies show RBD-ACE2 binding inhibition capacity and neutralization activity. Conclusion: Nasal immunization exhibits advantages in inducing immunity at the level of the nasopharyngeal mucosa in addition to the systemic response. |
| first_indexed | 2024-03-13T10:40:48Z |
| format | Article |
| id | doaj.art-2a6f95af70b440499537bd6dd130cc25 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-13T10:40:48Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-2a6f95af70b440499537bd6dd130cc252023-05-18T04:37:58ZengElsevierInternational Journal of Infectious Diseases1201-97122023-05-01130S10HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19G. Guillen0M. Limonta1V. Muzio2Z. Cinza3G. Lemos4G. Chinea5A. Martin6D. Gonzalez-Roche7I. Valdes8Y. Mendosa9J. Aguiar10M. Bequet11G. Marques12J. Zamora13E. Penton14E. Iglesias15J. Aguilar16O. Cruz17M. Ayala18E. Pimentel19E. Martinez20Center for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Clinical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Clinical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Development Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Development Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Production Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Biomedical Research Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, Production Direction, Havana, CubaCenter for Genetic Engineering and Biotechnology, General Direction, Havana, CubaBiotechnology and Pharmaceutical Industries Group, BioCubaFarma, Vice presidency, Havana, CubaBiotechnology and Pharmaceutical Industries Group, BioCubaFarma, Presidency, Havana, CubaIntro: The concept of training immunity originally developed for other diseases has gained attraction during the epidemic. Several clinical trials and epidemiological analyses of populations previously immunized with BCG and other vaccines were the focus of scientific discussions. Here we show the activation of innate immunity markers both at mucosal and systemic levels with a mucosal vaccine CIGB2020 (HeberNasvacTM) containing virus-like particles (HBsAg) and nucleocapsid particle (HBcAg) of the hepatitis B virus. Moreover, the immune potentiating capacity of the HBcAg combined with RBD protein was used to formulate a specific mucosal vaccine candidate against SARS-CoV-2 (MambisaTM). Methods: With CIGB 2020 (100µg HBsAg and 100 µg HBcAg) were conducted two proof of concept trials in human volunteers and a Phase I-II open, randomized, and controlled trial in 46 volunteers older than 60 years, symptomatic or close contact of COVID-19 patients. The volunteers were randomly assigned to the treatment group or not treated group. The nasal spray was administered to the treatment group on days 0, 7, and 14 together with daily sublingual administrations. Mucosal and serum samples were collected on days 0, 4, and 8. With MambisaTM vaccine (50µg RBD and 40 µg HBcAg) was conducted one proof of concept trial and a Phase I-II open and randomized trial in 1131 volunteers 19 to 60 years old, evaluating three different devices for nasal administration. All the volunteers gave written informed consent. Findings: CIGB2020 activates interferon-induced genes and TLR 3, 7, and 8 at the level of oropharyngeal mucosa and PBMC. Monocyte and lymphocyte populations were also activated. One dose of the MambisaTM vaccine induces high levels of specific IgG. The serum and mucosal antibodies show RBD-ACE2 binding inhibition capacity and neutralization activity. Conclusion: Nasal immunization exhibits advantages in inducing immunity at the level of the nasopharyngeal mucosa in addition to the systemic response.http://www.sciencedirect.com/science/article/pii/S1201971223001583 |
| spellingShingle | G. Guillen M. Limonta V. Muzio Z. Cinza G. Lemos G. Chinea A. Martin D. Gonzalez-Roche I. Valdes Y. Mendosa J. Aguiar M. Bequet G. Marques J. Zamora E. Penton E. Iglesias J. Aguilar O. Cruz M. Ayala E. Pimentel E. Martinez HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19 International Journal of Infectious Diseases |
| title | HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19 |
| title_full | HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19 |
| title_fullStr | HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19 |
| title_full_unstemmed | HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19 |
| title_short | HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19 |
| title_sort | hepatitis b nucleocapsid particle as immunopotentiator of innate and adaptive immunity for nasal vaccines cigb 2020 and mambisa against covid 19 |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223001583 |
| work_keys_str_mv | AT gguillen hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT mlimonta hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT vmuzio hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT zcinza hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT glemos hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT gchinea hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT amartin hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT dgonzalezroche hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT ivaldes hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT ymendosa hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT jaguiar hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT mbequet hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT gmarques hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT jzamora hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT epenton hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT eiglesias hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT jaguilar hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT ocruz hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT mayala hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT epimentel hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 AT emartinez hepatitisbnucleocapsidparticleasimmunopotentiatorofinnateandadaptiveimmunityfornasalvaccinescigb2020andmambisaagainstcovid19 |